NCT01188031View on ClinicalTrials.gov

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Healthy
Interventions
DRUG

ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG

A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions

DRUG

NIRAVAM TM 2 mg orally disintegrating tablets, single dose

B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT01188031 - A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter